The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
LRRK2, 2011Analytic Models in Biomarker Development
Objective/Rationale:
Non-invasive tests or biomarkers may aid clinical trials if they help to identify a subgroup of individuals at high risk of Parkinson's disease (PD), or if they are able to... -
Therapeutics Development Initiative, 2011Testing of Ambroxol in the Thy1-Alpha-Synuclein Pre-clinical Model of Parkinson's disease
Objective/Rationale:
Biochemical evidence suggests that blocking the maturation of a natural enzyme, glucocerebrosidase (GCase), can cause the build-up of alpha-synuclein deposits in neurons. Such... -
Research Grant, 2011Pre-clinical Development of Encapsulated Cell Biodelivery of GDNF for Parkinson's Disease
Objective/Rationale:
Glial cell line-derived neurotrophic factor (GDNF) is a protein that can aid in survival of the dopamine cells that die in Parkinson’s disease (PD). Treatment with GDNF in PD has... -
LRRK2 Cohort Consortium, 2011Autonomic Profiles of LRRK2 Mutation Carriers with Parkinson’s Disease and Non-manifesting, First-degree Relatives
Objective/Rationale:
Autonomic disturbances are common symptoms of Parkinson’s disease (PD). We propose to analyze data on autonomic function collected from PD patients and relatives of PD patients... -
LRRK2, 2011fMRI of First Degree Relatives of LRRK2 Positive Parkinson's Disease Patients
Objective/Rationale:
First, to study the effect of the presence of the LRRK2 G2019S mutation on brain activation patterns in PD patients who recently converted into a diseased state by comparing... -
LRRK2, 2011Increased Sensitivity to the Loss of Nigrostriatal Dopamine Following Progressive MPTP Treatment in LRRK2 Mutant Small Models
Objective/Rationale:
It is known that a mutation of specific gene, called LRRK2, increases the risks of developing Parkinson’s disease in humans. The specific objective of this proposal is to...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.